Table 2. Risk factors for severe or severe complicated CDI over non-severe CDI: a multivariate analysis
Ann Clin Microbiol 2022;25:17-23. Clinical and microbiological risk factors for severe Clostridioides difficile infections Risk factor OR (95% CI) P-value* Advanced age 1.017 (1.001-1.034) 0.0358 History of chemotherapy 2.695 (1.016-7.146) 0.0464 Ribotype 002 3.406 (1.183-9.803) 0.0231 *Statistical significances were maintained after the adjustment for age, associated disease (cancer, pneumonia, heart failure, nutrition deficiency), previous use […]
Table 1. Comparison of severe (or severe complicated) CDI and non-severe CDI
Ann Clin Microbiol 2022;25:17-23. Clinical and microbiological risk factors for severe Clostridioides difficile infections Variable Severe or severe complicated CDI(n = 149) Non-severe CDI(n = 155) P-value Age (yr) 74.0+15.0 65.9+18.3 < 0.0001 Sex, male 70 (47.0) 70 (45.2) 0.7505 Hospital-associated 100 (67.1) 94 (60.7) 0.2411 Charlson comorbidity index 2.4+1.7 2.5+1.8 0.6365 Associated disease Biliary […]
Table 3. Clinical course of patients with confirmed Plasmodium vivax infections
Ann Clin Microbiol 2022;25:11-16. Genetic polymorphisms in the pvdhfr, pvmdr1, and pvdhps genes of Plasmodium vivax in patients at a secondary hospital in South Korea Patient No. Medication Parasite count (/μL) [FU day*] Initial 1st FU 2nd FU 3rd FU 4th FU 5th FU 1 3 days of HCQ followed by 2 weeks of PQ […]
Table 2. Identified polymorphisms in pvdhfr of Plasmodium vivax
Ann Clin Microbiol 2022;25:11-16. Genetic polymorphisms in the pvdhfr, pvmdr1, and pvdhps genes of Plasmodium vivax in patients at a secondary hospital in South Korea Variants No. of cases pvdhfr F57L, C.292_309del 5 pvdhfr C.292_309del 2 pvdhfr H99S 3 pvdhfr S58R, S117N 1 pvdhfr C.292_309del & pvdhps M399I 1
Table 1. CBC results of patients with confirmed Plasmodium vivax infections
Ann Clin Microbiol 2022;25:11-16. Genetic polymorphisms in the pvdhfr, pvmdr1, and pvdhps genes of Plasmodium vivax in patients at a secondary hospital in South Korea Patient No. Sex Age (yr) WBC (103/μL) Hb (g/dL) PLT (103/μL) Neu (%) Lym (%) Mono (%) Eos (%) Baso (%) 1 M 22 3.55 15.1 42 81.0 12.0 6.0 […]
Table 4. Resistance profile of major gram-negative pathogens (2017-2019)
Ann Clin Microbiol 2022;25:1-10. Multidrug-resistant gram-negative bacterial infections the Tamale Teaching Hospital in Northern Ghana: a three-year retrospective analysis. Antibiotics No. of isolates (resistance %) Acinetobacter baumannii Enterobacter spp. Escherichia coli Klebsiella pneumoniae Pseudomonas aeruginosa AMK 7 (42.8) 198 (16.2) 383 (11.8) 425 (17.7) 242 (19.4) AMP NT 156 (98.7) 241 (97.9) 272 (97.4) NT […]
Table 3. MDR among isolated gram-negative bacteria (2017-2019)
Ann Clin Microbiol 2022;25:1-10. Multidrug-resistant gram-negative bacterial infections the Tamale Teaching Hospital in Northern Ghana: a three-year retrospective analysis. Species No. of isolates in a year (% of MDR isolates) 2017 2018 2019 Total Acinetobacter baumannii 4 (80.0) 3 (100.0) 3 (75.0) 10 (83.3) Citrobacter spp. 108 (89.1) 130 (92.9) 50 (98.0) 288 (91.4) Enterobacter […]
Table 2. Distribution of GNB from clinical samples cultured in 2017 -2019
Ann Clin Microbiol 2022;25:1-10. Multidrug-resistant gram-negative bacterial infections the Tamale Teaching Hospital in Northern Ghana: a three-year retrospective analysis. Species No. of isolates in the specimen (%) Blood GIT Respiratory Urine Wound Total Acinetobacter baumannii 3 (3.7) 1 (1.7) 3 (0.5) 7 (0.4) – 14 (0.5) Citrobacter spp. 9 (11.0) 2 (3.3) 44 (7.2) 215 […]
Table 1. The number of cultured gram-negative bacterial isolates distributed among age, sex, and specimen
Ann Clin Microbiol 2022;25:1-10. Multidrug-resistant gram-negative bacterial infections the Tamale Teaching Hospital in Northern Ghana: a three-year retrospective analysis. Characteristic Age (yr) Total <10 10-19 20-29 30-39 40-49 50-59 60-69 ≥ 70 Sex Female 162 91 402 300 163 82 81 126 1,407 Male 156 73 123 159 132 138 170 421 1,372 Specimen Aspirates […]
Table 1. Clinical characteristics, differences in Ct values and ELISA OD between neutralizing antibody-positive and -negative patients measured by microneutralization
Ann Clin Microbiol 2022;25:25-29. Analysis of neutralization antibodies in patients with mild COVID-19 infection after 100 days using microneutralization test Characteristic Neutralizing antibody P-value Positive (n = 9) No. (%) Negative (n = 21) No. (%) Total (n = 30) No. (%) Sex, male 5 (55.6) 8 (38.1) 13 (43.3) 0.630 Age (yr)* 53.4 ± […]